<DOC>
	<DOCNO>NCT00338026</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) recommend dose future study ECO-4601 administer continuous IV infusion 14 day 7 day recovery ( 21 day cycle ) patient histologically confirm solid tumor ( high grade glioma , colorectal , lung , breast , ovarian , pancreatic prostate ) . This study also design determine clinical pharmacokinetic profile , safety multiple cycle administration , document antitumor activity ECO-4601 .</brief_summary>
	<brief_title>A Phase I Study ECO-4601 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<criteria>Informed study consent participate study Clinically radiologically document advanced solid malignancy standard therapy available , fail standard therapy Patients follow solid tumor : high grade glioma , colorectal , prostate , pancreatic , lung , ovarian breast carcinoma Age ≥ 18 year age ECOG ≤ 2 Laboratory hematology biochemistry protocol test result abnormality ≤ Grade 1 , grade use NCI CTCAE version 3.0 Patients chemotherapy 4 week precede patient ' first dose ECO4601 ( day 1 , cycle 1 ) No anticancer treatment study Patients receive stable decrease dose steroid within 2 week prior patient 's signature inform consent Patients must accessible treatment followup . Patients register trial must treat follow participate centre Previous Therapy Hormonal therapy : Patients may prior hormonal therapy provide discontinue upon ICF signature Radiation : Patients may prior radiation therapy . Patients must recover acute toxic effect radiotherapy Previous surgery : Previous surgery permit provide least 2 week elapse major surgery ( nonbiopsy ) ICF signature Patients brain metastasis Unlikely comply protocol difficulty understand purpose study Life expectancy &lt; 12 week Clinically significant comorbid disease , e.g . renal failure , ischemic vascular disease , uncontrolled seizure , dementia Any patient potentially curable malignancy yet receive appropriate standard therapy Anti seizure drug know inducer cytochrome P450 Documented HIV , active hepatitis B C infection Patients active uncontrolled infection serious illness medical condition , would permit patient manage accord protocol Pregnant lactate woman ; men woman enrol study use adequate birth control measure throughout course study . Women childbearing potential must negative serum urine pregnancy test document within 14 day prior registration study start Inability refusal practice contraception therapy ECO4601 , unless patient surgically sterile woman postmenopausal least 2 year Patients treat investigational drug within 4 week patient 's signature inform consent form , receive concurrent treatment experimental drug anti cancer therapy Patients proper central line establish Concomitant therapy therapeutic coumadin ; patient transfer low molecular weight heparin Patients low molecular weight heparin &lt; 2 week prior ICF signature Polysorbate 80 major constituent ECO4601 know cause hypotension , patient uncontrolled hypotension exclude Known hypersensitivity farnesylated dibenzodiazepinone formulation component Concomitant Therapy Permitted : Patients may receive ongoing supportive palliative care ( eg : pain control ) clinically indicate throughout study . Patients treat corticosteroid medically need Usage low molecular weight heparin allow Anti seizure product permit provided inducer cytochrome P450 . Concomitant Therapy Not Permitted : Other anticancer treatment Other investigational therapy Concomitant therapy coumadin Cytochrome enzyme induce anti epileptic GCSF , GMCSF growth factor may use substitute schedule dose reduction ; however may use management acute toxicity febrile neutropenia clinically indicate discretion investigator . Use erythropoietin allow treatment initiate ≥ 2 month . Use growth factor must document case report form . Hormonal therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Thallion</keyword>
	<keyword>TLN-4601</keyword>
	<keyword>Ecopia</keyword>
	<keyword>ECO-4601</keyword>
	<keyword>Patients histologically confirm solid tumor :</keyword>
	<keyword>High Grade Glioma</keyword>
	<keyword>Colorectal</keyword>
	<keyword>Lung</keyword>
	<keyword>Breast</keyword>
	<keyword>Ovarian</keyword>
	<keyword>Pancreatic</keyword>
	<keyword>Prostate</keyword>
</DOC>